Nitric oxide-donating aspirin is focus of review of pharmacological and clinical perspectives

Nitric oxide-donating aspirin is focus of review of pharmacological and clinical perspectives

Drug Week - Apr. 28, 2006

2006 APR 28 - (NewsRx.com) -- A recent review describes the pharmacological profile of the NO-donating aspirin, NCX 4016, by addressing principally the pharmacological activity in inflammation and cardiovascular models.

According to a recent report from France, "In more than a century of use, the benefits of aspirin have been exploited in different therapeutic areas, from inflammation to cardiovascular disease for which it is an approved treatment for acute coronary heart disease and a recommended treatment for secondary cardiovascular prevention in patients at risk. Nitric oxide (NO), a small gaseous free radical molecule, is an important messenger of cellular and biological function that demonstrates an interesting anti-inflammatory profile and vascular protective activity."

"In addition," wrote M. Bolla and colleagues at NicOx in France, "NO exerts a protective action on the gastrointestinal mucosa. An elegant approach for exploiting the properties of both aspirin and NO, and for eventually increasing the overall activity of aspirin, has been to create a new molecule in which aspirin and a NO-donating group are covalently linked (NCX 4016). This molecule requires enzymatic metabolism to release both components in order to provide simultaneous actions."

"NCX 4016 has been shown to retain the anti-inflammatory properties of aspirin and therefore possesses the same efficacy as aspirin in animal models of pain and inflammation," they continued. "In addition, the release of NO accounts for the inhibition of the release of some cytokines. In cardiovascular models, NCX 4016 shows a better efficacy than aspirin in counteracting thrombo-embolism, myocardial infarction and vascular reactivity and remodeling (restenosis)."

"This review describes the pharmacological profile of the NO-donating aspirin, NCX 4016, by addressing principally the pharmacological activity in inflammation and cardiovascular models. Gastrointestinal safety is specifically addressed," the authors noted. "The potential clinical use of NCX 4016 in vascular pathologies is also discussed."

Bolla and colleagues published their study in the European Journal of Clinical Pharmacology (Nitric oxide-donating aspirin (NCX 4016): an overview of its pharmacological properties and clinical perspectives. Eur J Clin Pharmacol, 2006;62(Suppl. 13):145-154).

For additional information, contact M. Bolla, NicOx SA, 2455 Route Dolines, BP 313, F-06906 Sophia-Antipolis Cedex, France.

Publisher contact information for the European Journal of Clinical Pharmacology is: Springer, 233 Spring Street, New York, NY 10013, USA.

Keywords: Sophia-Antipolis, France, Angiology, Anti-inflammatory, Aspirin, Cardiology, Cardiovascular Disease, Drugs, Embolism, Enzymology, Gastroenterology, Inflammation, Myocardial Infarction, NCX 4016, Pharmaceuticals, Thrombo-embolism.

This article was prepared by Drug Week editors from staff and other reports. Copyright 2006, Drug Week via NewsRx.com.

Source